- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DIVIS LABORATORIES - GLENMARK PHARMA
DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results
DIVIS LABORATORIES 
Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
GLENMARK PHARMA
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| DIVIS LABORATORIES | GLENMARK PHARMA | DIVIS LABORATORIES/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 39.3 | 25.1 | 156.7% | View Chart |
| P/BV | x | 6.4 | 3.9 | 162.2% | View Chart |
| Dividend Yield | % | 0.7 | 0.3 | 229.1% |
Financials
 DIVIS LABORATORIES  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-18 |
GLENMARK PHARMA Mar-17 |
DIVIS LABORATORIES/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,142 | 993 | 115.0% | |
| Low | Rs | 533 | 729 | 73.1% | |
| Sales per share (Unadj.) | Rs | 146.6 | 325.5 | 45.0% | |
| Earnings per share (Unadj.) | Rs | 33.0 | 39.3 | 84.1% | |
| Cash flow per share (Unadj.) | Rs | 38.4 | 48.7 | 78.9% | |
| Dividends per share (Unadj.) | Rs | 10.00 | 2.00 | 500.0% | |
| Dividend yield (eoy) | % | 1.2 | 0.2 | 514.2% | |
| Book value per share (Unadj.) | Rs | 222.8 | 159.2 | 140.0% | |
| Shares outstanding (eoy) | m | 265.47 | 282.17 | 94.1% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 5.7 | 2.6 | 216.0% | |
| Avg P/E ratio | x | 25.3 | 21.9 | 115.7% | |
| P/CF ratio (eoy) | x | 21.8 | 17.7 | 123.2% | |
| Price / Book Value ratio | x | 3.8 | 5.4 | 69.5% | |
| Dividend payout | % | 30.3 | 5.1 | 594.7% | |
| Avg Mkt Cap | Rs m | 222,318 | 242,991 | 91.5% | |
| No. of employees | `000 | 10.8 | 13.0 | 83.0% | |
| Total wages/salary | Rs m | 4,561 | 16,408 | 27.8% | |
| Avg. sales/employee | Rs Th | 3,616.0 | 7,083.9 | 51.0% | |
| Avg. wages/employee | Rs Th | 423.8 | 1,265.4 | 33.5% | |
| Avg. net profit/employee | Rs Th | 814.9 | 855.1 | 95.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 38,915 | 91,857 | 42.4% | |
| Other income | Rs m | 1,134 | 374 | 303.6% | |
| Total revenues | Rs m | 40,049 | 92,230 | 43.4% | |
| Gross profit | Rs m | 12,617 | 20,367 | 61.9% | |
| Depreciation | Rs m | 1,425 | 2,644 | 53.9% | |
| Interest | Rs m | 13 | 2,373 | 0.6% | |
| Profit before tax | Rs m | 12,313 | 15,724 | 78.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -810 | 0.0% | |
| Tax | Rs m | 3,543 | 3,827 | 92.6% | |
| Profit after tax | Rs m | 8,770 | 11,088 | 79.1% | |
| Gross profit margin | % | 32.4 | 22.2 | 146.2% | |
| Effective tax rate | % | 28.8 | 24.3 | 118.2% | |
| Net profit margin | % | 22.5 | 12.1 | 186.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 45,351 | 68,746 | 66.0% | |
| Current liabilities | Rs m | 6,507 | 27,027 | 24.1% | |
| Net working cap to sales | % | 99.8 | 45.4 | 219.8% | |
| Current ratio | x | 7.0 | 2.5 | 274.0% | |
| Inventory Days | Days | 127 | 85 | 149.0% | |
| Debtors Days | Days | 95 | 96 | 99.6% | |
| Net fixed assets | Rs m | 21,160 | 24,132 | 87.7% | |
| Share capital | Rs m | 531 | 282 | 188.1% | |
| "Free" reserves | Rs m | 58,625 | 44,643 | 131.3% | |
| Net worth | Rs m | 59,156 | 44,925 | 131.7% | |
| Long term debt | Rs m | 0 | 45,363 | 0.0% | |
| Total assets | Rs m | 67,832 | 117,639 | 57.7% | |
| Interest coverage | x | 926.8 | 7.6 | 12,154.0% | |
| Debt to equity ratio | x | 0 | 1.0 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.8 | 73.5% | |
| Return on assets | % | 12.9 | 11.4 | 113.2% | |
| Return on equity | % | 14.8 | 24.7 | 60.1% | |
| Return on capital | % | 20.8 | 19.1 | 108.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 21.8 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | 8,485 | NA | - | |
| Fx inflow | Rs m | 32,359 | 56,152 | 57.6% | |
| Fx outflow | Rs m | 9,042 | 8,084 | 111.9% | |
| Net fx | Rs m | 23,317 | 48,068 | 48.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,759 | 6,574 | 118.0% | |
| From Investments | Rs m | -4,783 | -7,124 | 67.1% | |
| From Financial Activity | Rs m | -3,142 | 5,432 | -57.8% | |
| Net Cashflow | Rs m | -166 | 1,992 | -8.3% | |
Share Holding
| Indian Promoters | % | 52.0 | 48.3 | 107.7% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 11.8 | 6.9 | 171.0% | |
| FIIs | % | 19.0 | 34.4 | 55.2% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.2 | 10.5 | 163.8% | |
| Shareholders | 31,796 | 56,727 | 56.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: ABBOTT INDIA NATCO PHARMA BIOCON LTD PFIZER ALKEM LABORATORIES
Compare DIVIS LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)
Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.
Related Views on News
GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)
Nov 7, 2017Poor show in the US, Latam and India hit profits during the quarter.
Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)
Oct 30, 2017The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My First Pharma Stock Recommendation!(The 5 Minute Wrapup)
Sep 21, 2018This company has not only created a niche in the pharma space, it has done so profitably.
Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)
Sep 21, 2018Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)
Sep 17, 2018PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.
How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)
Sep 19, 2018PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.
More|
| |
DIVIS LABORATORIES SHARE PRICE
Sep 26, 2018 10:19 AM
TRACK DIVIS LABORATORIES
- Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DIVIS LABORATORIES
DIVIS LABORATORIES 5-YR ANALYSIS
COMPARE DIVIS LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.